Cardiff Oncology (CRDF) News Today $4.20 -0.12 (-2.78%) (As of 10:51 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownershipDecember 23, 2024 | finance.yahoo.comCraig-Hallum Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)December 17, 2024 | markets.businessinsider.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 6.0%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 8,180,000 shares, a growth of 6.0% from the November 15th total of 7,720,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover ratio is presently 5.5 days.December 16, 2024 | marketbeat.comTD Cowen Keeps Their Buy Rating on Cardiff Oncology (CRDF)December 14, 2024 | markets.businessinsider.comCardiff Oncology (NASDAQ:CRDF) Price Target Raised to $10.00 at Piper SandlerPiper Sandler raised their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a report on Friday.December 13, 2024 | marketbeat.comInsider Buying: Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Buys 350,115 Shares of StockDecember 13, 2024 | insidertrades.comCardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just BeginningDecember 12, 2024 | seekingalpha.comCardiff Oncology (CRDF) Gets a Buy from Craig-HallumDecember 11, 2024 | markets.businessinsider.comCardiff Oncology Reports Promising Phase 2 Trial ResultsDecember 11, 2024 | finance.yahoo.comCardiff Oncology (NASDAQ:CRDF) Stock, Short Interest ReportDecember 11, 2024 | benzinga.comCardiff Oncology prices $40M registered direct offering at $2.60 per shareDecember 11, 2024 | markets.businessinsider.comCardiff Oncology (NASDAQ:CRDF) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comCardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal CancerDecember 10, 2024 | seekingalpha.comCardiff Oncology Shares Rise 45% On Initial Positive Results in Colon Cancer TrialDecember 10, 2024 | marketwatch.comCardiff Oncology Prices About $40 Mln Oversubscribed Offering To Fund Colorectal Cancer TrialsDecember 10, 2024 | markets.businessinsider.comCardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical TrialDecember 10, 2024 | globenewswire.comCardiff Oncology announces new patent with claims for onvansertibNovember 19, 2024 | markets.businessinsider.comCardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRCNovember 19, 2024 | markets.businessinsider.comCardiff Oncology price target lowered to $13 from $14 at H.C. WainwrightNovember 9, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)November 8, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for Cardiff Oncology (NASDAQ:CRDF) Stock PriceHC Wainwright dropped their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a "buy" rating for the company in a report on Friday.November 8, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 77.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 270,523 shaNovember 3, 2024 | marketbeat.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 7.2%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 7,320,000 shares, an increase of 7.2% from the September 30th total of 6,830,000 shares. Based on an average daily volume of 495,200 shares, the days-to-cover ratio is presently 14.8 days.November 1, 2024 | marketbeat.comCardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRCOctober 30, 2024 | globenewswire.comCardiff Oncology Inc (CRDF) Q2 2024 Earnings Call Highlights: Strategic Trials and Financial ...October 9, 2024 | finance.yahoo.comCraig-Hallum Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationSeptember 6, 2024 | msn.comCardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Craig HallumCraig Hallum began coverage on Cardiff Oncology in a research note on Friday. They set a "buy" rating and a $8.00 price objective on the stock.September 6, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short InterestCardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 6,720,000 shares, a growth of 16.3% from the July 31st total of 5,780,000 shares. Based on an average daily trading volume, of 573,000 shares, the short-interest ratio is presently 11.7 days.September 2, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys 962,940 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)Assenagon Asset Management S.A. increased its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 380.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,215,922 shareAugust 21, 2024 | marketbeat.comEarnings call: Cardiff Oncology Q2 2024 update on CRDF-004 trial and financesAugust 15, 2024 | uk.investing.comCardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comWhat Wall Street expects from Cardiff Oncology's earningsAugust 7, 2024 | markets.businessinsider.comCardiff Oncology (CRDF) Set to Announce Quarterly Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.August 2, 2024 | marketbeat.comCompanies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In GrowthJuly 24, 2024 | finance.yahoo.comCardiff Oncology (NASDAQ:CRDF) Trading 0.7% Higher Cardiff Oncology (NASDAQ:CRDF) Shares Up 0.7%June 11, 2024 | marketbeat.comCardiff Oncology to Present at the Jefferies Healthcare ConferenceMay 29, 2024 | globenewswire.comAssenagon Asset Management S.A. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)Assenagon Asset Management S.A. acquired a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 252,982 shares of the company's stock,May 20, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest UpdateCardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 4,420,000 shares, an increase of 10.8% from the April 15th total of 3,990,000 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 2.3 days.May 17, 2024 | marketbeat.comCardiff Oncology to Present at Upcoming Investor Conferences in MayMay 13, 2024 | globenewswire.comHC Wainwright Analysts Raise Earnings Estimates for Cardiff Oncology, Inc. (NASDAQ:CRDF)Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Cardiff Oncology in a report released on Monday, May 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings perMay 9, 2024 | marketbeat.comCardiff Oncology (NASDAQ:CRDF) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Cardiff Oncology in a research note on Monday.May 6, 2024 | marketbeat.comCardiff Oncology First Quarter 2024 Earnings: Beats ExpectationsMay 4, 2024 | finance.yahoo.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call TranscriptMay 3, 2024 | msn.comCardiff Oncology Inc (CRDF) (Q1 2024) Earnings Call Transcript Highlights: Strategic Insights ...May 3, 2024 | finance.yahoo.comCRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | investorplace.comCardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateMay 2, 2024 | globenewswire.comCardiff Oncology (CRDF) Set to Announce Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.May 1, 2024 | marketbeat.comCardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateApril 25, 2024 | globenewswire.comCardiff Oncology, Inc. (NASDAQ:CRDF) Forecasted to Earn Q1 2025 Earnings of ($0.28) Per ShareCardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at William Blair issued their Q1 2025 EPS estimates for Cardiff Oncology in a note issued to investors on Tuesday, April 9th. William Blair analyst A. Hsieh anticipates that the company will earn ($0.28) per share for the quarter. TheApril 12, 2024 | marketbeat.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?April 9, 2024 | investorplace.com Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Grab This Altcoin Before Trump's Crypto Announcement (Ad)Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. Click here to check it out now CRDF Media Mentions By Week CRDF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDF News Sentiment▼0.550.59▲Average Medical News Sentiment CRDF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDF Articles This Week▼41▲CRDF Articles Average Week Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRTA News Today PLRX News Today CRON News Today RLAY News Today TYRA News Today ERAS News Today TECX News Today KROS News Today KURA News Today CGEM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDF) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
